These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 28011907)

  • 1. Development of a Global Respiratory Severity Score for Respiratory Syncytial Virus Infection in Infants.
    Caserta MT; Qiu X; Tesini B; Wang L; Murphy A; Corbett A; Topham DJ; Falsey AR; Holden-Wiltse J; Walsh EE
    J Infect Dis; 2017 Mar; 215(5):750-756. PubMed ID: 28011907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hospitalization for respiratory syncytial virus bronchiolitis and disease severity in twins.
    Dotan M; Ashkenazi-Hoffnung L; Samra Z; Livni G; Yarden-Bilavsky H; Amir J; Bilavsky E
    Isr Med Assoc J; 2013 Nov; 15(11):701-4. PubMed ID: 24511652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
    Simoes EA; Carbonell-Estrany X
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity.
    Lanari M; Giovannini M; Giuffré L; Marini A; Rondini G; Rossi GA; Merolla R; Zuccotti GV; Salvioli GP;
    Pediatr Pulmonol; 2002 Jun; 33(6):458-65. PubMed ID: 12001280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and epidemiological impact of respiratory syncytial virus and identification of risk factors for severe disease in children hospitalized due to acute respiratory tract infection.
    Ferolla FM; Soffe J; Mistchenko A; Contrini MM; López EL
    Arch Argent Pediatr; 2019 Aug; 117(4):216-223. PubMed ID: 31339263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Respiratory syncytial virus hospitalization outcomes and costs of full-term and preterm infants.
    McLaurin KK; Farr AM; Wade SW; Diakun DR; Stewart DL
    J Perinatol; 2016 Nov; 36(11):990-996. PubMed ID: 27490190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of the Global Respiratory Severity Score for predicting the need for respiratory support in infants with respiratory syncytial virus infection.
    Kubota J; Hirano D; Okabe S; Yamauchi K; Kimura R; Numata H; Suzuki T; Kakegawa D; Ito A
    PLoS One; 2021; 16(7):e0253532. PubMed ID: 34197495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory Syncytial Virus Consortium in Europe (RESCEU) Birth Cohort Study: Defining the Burden of Infant Respiratory Syncytial Virus Disease in Europe.
    Wildenbeest JG; Zuurbier RP; Korsten K; van Houten MA; Billard MN; Derksen-Lazet N; Snape MD; Drysdale SB; Robinson H; Pollard AJ; Heikkinen T; Cunningham S; Leach A; Martinón-Torres F; Rodríguez-Tenreiro Sánchez C; Gómez-Carballa A; Bont LJ;
    J Infect Dis; 2020 Oct; 222(Suppl 7):S606-S612. PubMed ID: 32794574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of a risk scoring tool to predict respiratory syncytial virus disease severity and need for hospitalization in term infants.
    Mosalli R; Abdul Moez AM; Janish M; Paes B
    J Med Virol; 2015 Aug; 87(8):1285-91. PubMed ID: 25784593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk-Scoring Tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada.
    Paes B; Steele S; Janes M; Pinelli J
    Curr Med Res Opin; 2009 Jul; 25(7):1585-91. PubMed ID: 19469698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
    Resch B; Egger B; Kurath-Koller S; Urlesberger B
    Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza and respiratory syncytial virus in infants study (IRIS) of hospitalized and non-ill infants aged <1 year in four countries: study design and methods.
    Thompson MG; Hunt DR; Arbaji AK; Simaku A; Tallo VL; Biggs HM; Kulb C; Gordon A; Khader IA; Bino S; Lucero MG; Azziz-Baumgartner E; Shifflett P; Sanchez F; Marar BI; Bakalli I; Simões EA; Levine MZ; Meece JK; Balmaseda A; Al-Sanouri TM; Dhimolea M; de Jesus JN; Thornburg NJ; Gerber SI; Gresh L;
    BMC Infect Dis; 2017 Mar; 17(1):222. PubMed ID: 28330443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness.
    Ramilo O; Lagos R; Sáez-Llorens X; Suzich J; Wang CK; Jensen KM; Harris BS; Losonsky GA; Griffin MP;
    Pediatr Infect Dis J; 2014 Jul; 33(7):703-9. PubMed ID: 24356256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Risk factors for acute respiratory syncytial virus infection of lower respiratory tract in hospitalized infants].
    Zhang X; Liu L; Shi P; Jiang G; Jia P; Wang C; Wang L; Qian L
    Zhonghua Er Ke Za Zhi; 2014 May; 52(5):373-7. PubMed ID: 24969937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory syncytial virus, human bocavirus and rhinovirus bronchiolitis in infants.
    Midulla F; Scagnolari C; Bonci E; Pierangeli A; Antonelli G; De Angelis D; Berardi R; Moretti C
    Arch Dis Child; 2010 Jan; 95(1):35-41. PubMed ID: 19822538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy.
    Bradley JP; Bacharier LB; Bonfiglio J; Schechtman KB; Strunk R; Storch G; Castro M
    Pediatrics; 2005 Jan; 115(1):e7-14. PubMed ID: 15629968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI).
    Straňák Z; Saliba E; Kosma P; Posfay-Barbe K; Yunis K; Farstad T; Unnebrink K; van Wyk J; Wegzyn C; Notario G; Kalus S; Campbell FJ
    PLoS One; 2016; 11(6):e0157446. PubMed ID: 27310438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.
    Figueras-Aloy J; Carbonell-Estrany X; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
    Pediatr Infect Dis J; 2008 Sep; 27(9):788-93. PubMed ID: 18664927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age.
    Hall CB; Weinberg GA; Blumkin AK; Edwards KM; Staat MA; Schultz AF; Poehling KA; Szilagyi PG; Griffin MR; Williams JV; Zhu Y; Grijalva CG; Prill MM; Iwane MK
    Pediatrics; 2013 Aug; 132(2):e341-8. PubMed ID: 23878043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.